ReviewJournal of biomedicine & biotechnology2010
Vaccines against human carcinomas: strategies to improve antitumor immune responses.
Review in Journal of biomedicine & biotechnology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 57 citations in OpenAlex.
- Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Trial
- Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer.Cancer immunology, immunotherapy : CII · 2015Trial
- Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.Cancer immunology, immunotherapy : CII · 2013Trial
- Article
- Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition.Cells, tissues, organs · 2017Review
- Endogenous immunity at the forefront of tumor dormancy.Future science OA · 2015Article
- A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2015Article
- Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State.Vaccines · 2015Review
- The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.The oncologist · 2015Review
- Clinically feasible approaches to potentiating cancer cell-based immunotherapies.Human vaccines & immunotherapeutics · 2015Review
- Immune Targeting of Tumor Epithelial-Mesenchymal Transition via Brachyury-Based Vaccines.Advances in cancer research · 2015Review
- Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.Human vaccines & immunotherapeutics · 2014Review
- Article
- [Immunotherapy for non-small cell lung cancer--novel approaches to improve patient outcome].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2013Review
- Cancer vaccines: Looking to the future.Oncoimmunology · 2013Article
- Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas.BMC clinical pathology · 2012Article
- Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.Immunotherapy · 2011Review
- Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells.Experimental biology and medicine (Maywood, N.J.) · 2011Review
- Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine.Cancer immunology, immunotherapy : CII · 2011Article
- Vaccines targeting the neovasculature of tumors.Vascular cell · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Multiple observations in preclinical and clinical studies support a role for the immune system in controlling tumor growth and progression. Various components of the innate and adaptive immune response are able to mediate tumor cell destruction; however, certain immune cell populations can also induce a protumor environment that favors tumor growth and the development of metastasis. Moreover, tumor cells themselves are equipped with various mechanisms that allow them to evade surveillance by the immune system. The goal of cancer vaccines is to induce a tumor-specific immune response that ultimately will reduce tumor burden by tipping the balance from a protumor to an antitumor immune environment. This review discusses common mechanisms that govern immune cell activation and tumor immune escape, and some of the current strategies employed in the field of cancer vaccines aimed at enhancing activation of tumor-specific T-cells with concurrent reduction of immunosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.